We are live on ! Find out more
CRXT

Clarus Therapeutics Holdings, Inc. Common Stock
CRXT

Delisted

CRXT was delisted on the 30th of August, 2022.

Back to rankings

2 hedge funds and large institutions have $5K invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less funds holding

Funds holding: 25 → 2 (-23)

100% less capital invested

Capital invested by funds: $1.82M → $5K (-$1.82M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 23

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-23
Holders Change %
-92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCL
Bracebridge Capital LLC
Massachusetts
-$761K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$397K
3
BlackRock
BlackRock
New York
-$124K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$115K
5
VF
Virtu Financial
New York
-$72K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$5K -$16.3K -53,100 -27%
BCL
2
Bracebridge Capital LLC
Massachusetts
– -$761K -2,002,495 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$397K -1,039,148 Closed
BlackRock
4
BlackRock
New York
– -$124K -323,800 Closed
Geode Capital Management
5
Geode Capital Management
Massachusetts
– -$115K -301,652 Closed
VF
6
Virtu Financial
New York
– -$72K -188,086 Closed
Millennium Management
7
Millennium Management
New York
– -$65K -170,520 Closed
Renaissance Technologies
8
Renaissance Technologies
New York
– -$47K -122,277 Closed
CAN
9
Cetera Advisor Networks
California
– -$24K -63,000 Closed
PIA
10
Powell Investment Advisors
Florida
– -$23K -60,000 Closed
WAM
11
Warberg Asset Management
Illinois
– -$21K -55,000 Closed
BCM
12
Bridgeway Capital Management
Texas
– -$17K -45,000 Closed
AC
13
Ayrton Capital
Connecticut
– -$12K -32,525 Closed
Verition Fund Management
14
Verition Fund Management
Connecticut
– -$11K -30,004 Closed
Squarepoint
15
Squarepoint
New York
– -$11K -29,085 Closed
State Street
16
State Street
Massachusetts
– -$10K -25,536 Closed
UBS Group
17
UBS Group
Switzerland
– -$9K -23,534 Closed
Citigroup
18
Citigroup
New York
– -$7K -18,000 Closed
SG
19
StoneX Group
New York
– -$4.46K -11,685 Closed
Two Sigma Investments
20
Two Sigma Investments
New York
– -$4K -10,001 Closed
Osaic Holdings
21
Osaic Holdings
Arizona
– -$4K -10,000 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$3K -6,957 Closed

CRXT Hedge Fund Activity: Q3 2022 in Review

2 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q3 2022, worth a combined $5K — down 100% from $1.82M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CRXT and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Bracebridge Capital LLC, exiting entirely with an estimated $761K sold.

  • 2 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q3 2022, down from 25 in Q2 2022.
  • Funds reported $5K of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q3 2022 and 23 closed out, a net change of -23 holders.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q3 2022 was Bracebridge Capital LLC, an estimated $761K sold.

Based on aggregated 13F filings for Q3 2022.